| 영문 | rheumatoid factor | 한글 | 류마티스 인자 |
|---|---|---|---|
| 설명 | IgG의 Fc부위에 있는 항원결정인자에 대한 항체로서 전형적인 또는 확실한 류마티스관절염(rheumatoid arthritis) 환자의 80%에서 발견된다. 류마티스 인자는 IgM, IgG, IgA중 하나가 될 수 있으나 주로 IgM이다. 소아류마티스관절염(juvenile rheumatoid arthritis: 소아기에 발생하는 류마티스관절염)을 비롯한, 다른 결합조직병이나 감염병에도 나타날 수 있다 |
||
| 영문 | growth factor | 한글 | 성장인자 |
|---|---|---|---|
| 설명 | 세포의 분화 및 성장에 관여하는 단백질. 성장인자는 정상 세포주기에 필수적이기 때문에 동물의 생명에 중대한 요소가 된다. 무엇보다도 성장인자는 태아의 발육을 조정하고 조직의 유지 및 보수에 중대한 역할을 하며, 혈구의 생성을 자극한다. 또한 암의 진행과정에도 관여한다. |
||
| 영문 | risk factor | 한글 | 위험인자 |
|---|---|---|---|
| 설명 | 국제방사선방호위원회(ICRP)가 1977년 권고에서 방사선방호의 목적으로 채택한 지수로, 단위선량(1 Sv)당 확률적 영향의 발생확률을 추정하여 나타낸 것이다. 생식선 선량에 대한 유전적영향의 발생률(4×10－3/Sv)이나 적색골수선량에 대한 백혈병 발생률(2×10－3/Sv)등 외에 뼈, 허파, 갑상샘, 젖샘, 기타 조직의 위험지수를 측정하여, 확률적 영향의 전신에 있어서 치사위험지수의 합계를 16.5×10－3/Sv로 하였다. 그후 ICRP는 1990년 권고에서 대상이 되는 조직과 장기를 추가하고, 수치 개정을 하면서 명칭도 각목적확률지수라고하였다. 이 권고에 의하면, 치사적 확률적 영향의 확률지수의 합계는, 일반인에 있어 60.0×10－3/Sv이다. |
||
| MIF | macrophage inhibitory factor; melanocyte[-stimulating hormone]-inhibiting factor; maximum inspirator... |
|---|---|
| PIF | paratoid isoelectric focusing variant protein; peak inspiratory flow; proinsulin-free; prolactin-inh... |
| CF | calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ... |
| RIF | radiological interface; release-inhibiting factor; rifampin; right iliac fossa; rosette-inhibiting f... |
| EF | ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e... |
| GIF | Glycosylation inhibiting factor |
|---|---|
| PIF | Prolactin Inhibiting Factor |
| PIF | Prolactin release-inhibiting factor |
| SRIF | Somatotropin Release Inhibiting Factor |
| GH-RIH | Growth hormone release inhibiting hormone |
IGF-II : insulin like growth factor-II의 약자. 많은 장기와 조직에 작용하여 단백 합성과 DNA, RNA의 합성을 증가시켜 세포의 수와 양을 증가
| luteinization | Transformation of the mature ovarian follicle and its theca interna into a corpus luteum after ovulation; formation of luteal tissue, which appears yellow in some species. (05 Mar 2000) |
|---|---|
| mullerian inhibiting factor | A 535 amino acid glycoprotein secreted by the Sertoli cells of the testis. It is related to inhibin. Synonym: mullerian inhibiting factor. (05 Mar 2000) |
| prolactin-inhibiting factor | A substance of hypothalamic origin capable of inhibiting the synthesis and release of prolactin. Synonym: prolactin-inhibiting factor, prolactin-inhibiting hormone. Origin: prolactin + G. Stasis, standing still, + -in (05 Mar 2000) |
| somatotropin release-inhibiting factor | <protein> Gastrointestinal and hypothalmic peptide hormone (two forms: 14 and 28 residues), found in gastric mucosa, pancreatic islets, nerves of the gastrointestinal tract, in posterior pituitary and in the central nervous system. Inhibits gastric secretion and motility: in hypothalamus/pituitary inhibits somatotropin release. (18 Nov 1997) |
| melanotropin release-inhibiting hormone | Inhibits synthesis and release of melanotropin. Synonym: melanotropin release-inhibiting hormone. Origin: melanotropin + G. States, stationary, + -in (05 Mar 2000) |
| growth hormone inhibiting hormone | <protein> Gastrointestinal and hypothalmic peptide hormone (two forms: 14 and 28 residues), found in gastric mucosa, pancreatic islets, nerves of the gastrointestinal tract, in posterior pituitary and in the central nervous system. Inhibits gastric secretion and motility: in hypothalamus/pituitary inhibits somatotropin release. (18 Nov 1997) |
| pituitary hormone release inhibiting hormones | Polypeptide hormones produced in the hypothalamus which inhibit the release of pituitary hormones. (12 Dec 1998) |
| msh release-inhibiting hormone | <chemical> An oligopeptide hormone produced in the hypothalamus that inhibits the release of melanocyte-stimulating hormone (msh). Chemical name: Melanostatin (12 Dec 1998) |
| mullerian inhibiting substance | A 535 amino acid glycoprotein secreted by the Sertoli cells of the testis. It is related to inhibin. Synonym: mullerian inhibiting factor. (05 Mar 2000) |
| prolactin-inhibiting hormone | A substance of hypothalamic origin capable of inhibiting the synthesis and release of prolactin. Synonym: prolactin-inhibiting factor, prolactin-inhibiting hormone. Origin: prolactin + G. Stasis, standing still, + -in (05 Mar 2000) |
| prolactin release-inhibiting hormone | <chemical> A polypeptide hormone produced in the hypothalamus that inhibits the release of prolactin. Chemical name: Prolactin release-inhibiting factor (12 Dec 1998) |
| somatotropin release-inhibiting hormone | <protein> Gastrointestinal and hypothalmic peptide hormone (two forms: 14 and 28 residues), found in gastric mucosa, pancreatic islets, nerves of the gastrointestinal tract, in posterior pituitary and in the central nervous system. Inhibits gastric secretion and motility: in hypothalamus/pituitary inhibits somatotropin release. (18 Nov 1997) |
| inhibiting antibody | An "incomplete" form of antibody that may coat antigen, but which according to the "lattice theory" does not have a second receptor for attachment to another molecule of antigen; in the case of Rh+ erythrocytes, such an anti-Rh antibody may coat the cells but not cause them to agglutinate in saline; however, agglutination does occur when such coated cells are suspended in serum or other protein media, such as albumin, therefore called serum agglutinin. Synonym: incomplete antibody, inhibiting antibody. (05 Mar 2000) |
| accelerator factor | <chemical> Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor v accomplishes this by forming a complex with factor xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor v leads to owren's disease. Chemical name: Blood-coagulation factor V (12 Dec 1998) |
| acetate replacement factor | <biochemistry> 1,2 dithiolane 3 valeric acid. Regarded as a coenzyme in the oxoglutarate dehydrogenase complex of the citric acid cycle. Involved generally in oxidative decarboxylations of _ keto acids. A growth factor for some organisms. (18 Nov 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|